November 6, 2023 07:06 AM EST
R&D

As­traZeneca, Ele­don and Alpine spell out kid­ney pro­gram suc­cess­es: ASN roundup

Ayisha Sharma

News Reporter

Over the past few days, Big Phar­ma and biotech com­pa­nies alike pre­sent­ed re­sults at the Amer­i­can So­ci­ety of Nephrol­o­gy’s an­nu­al kid­ney week. End­points News sift­ed …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

FDA ap­proves Hu­ma­cyte’s lab-grown blood ves­sels in mile­stone for re­gen­er­a­tive med­i­cine

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

Ex­clu­sive: Flori­da can­cer biotech rais­es $100M Se­ries A

Califf, on his way out at FDA, pre­dicts agency tug-of-war be­tween Ra­maswamy and RFK Jr.

Ac­cel­er­at­ed ap­proval brings Pfiz­er's BRAF in­hibitor to first-line pa­tients

Sofinno­va out­lines $550M fund af­ter IPOs and M&A deals

A service from the Financial Times